Latest Content

Psyence BioMed phase 2b trial explores psilocybin therapy for adjustment disorder in palliative care, aiming for groundbreaking treatment advancements.

Submit articles, 1000 to 1800 words in length, on use of the PRiSM instrument in research or clinical practice by January 31, 2026.

Eleanor Roosevelt's legacy inspires today's leaders to champion human rights, emphasizing mental health and the ongoing fight against discrimination.

AtaiBeckley reveals promising phase 2b open-label extension study results for BPL-003, showing sustained antidepressant effects in patients with treatment-resistant depression after redosing.

FDA approves Caplyta for major depressive disorder, a new sNDA for Alzheimer disease, and news in correctional psychiatry.

Mentalization-based treatment offers innovative strategies to effectively address the challenges of narcissistic personality disorder and enhance emotional understanding.

Explore the profound connections between Thornton Wilder's "Our Town," psychiatry, and the importance of appreciating life's everyday moments.

Explore the intertwined stories of Lucy Grealy and Anne Patchett, revealing deep insights into mental health, beauty, and friendship.

Explore the vital connection between spirituality and mental health.

Submit to our writing contest for the opportunity to win publication in Psychiatric Times and a $500 prize!

Johnson & Johnson's Caplyta gains FDA approval as an adjunctive treatment for major depressive disorder, offering hope for improved patient outcomes.

Explore the intersection of AI and mental health, specifically the implications of technology on clinician well-being and ethical psychiatry.

Answer our poll!